Trial Profile
A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs GLPG 1837 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Acronyms SAPHIRA 1
- Sponsors Galapagos NV
- 20 Dec 2016 Results published in the Galapagos NV media release.
- 09 Dec 2016 This trial was completed in Germany (end date: 2016-10-06), according to European Clinical Trials Database.
- 06 Dec 2016 Status changed from recruiting to completed.